Switch theme
Sign up to access all valuation multiples
Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based pharmaceutical manufacturer. The company is primarily engaged in the manufacturing, research, development, and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst, and lithium battery materials. Its active pharmaceutical ingredient offerings include Carbamazepine, Duloxetine, Bezafibrate, Meropenem, Sulphadimethoxine Sodium, Oxcarbazepine, and Amprolium, among others. The firm also provides services of new drug contract development and manufacturing organization to the international pharmaceutical giant.
1973
4.9K+
LTM Revenue $736M
LTM EBITDA $172M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiuzhou Pharmaceutical has a last 12-month revenue of $736M and a last 12-month EBITDA of $172M.
In the most recent fiscal year, Jiuzhou Pharmaceutical achieved revenue of $711M and an EBITDA of $160M.
Jiuzhou Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiuzhou Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $761M | $711M | XXX | XXX | XXX |
| Gross Profit | $260M | $287M | XXX | XXX | XXX |
| Gross Margin | 34% | 40% | XXX | XXX | XXX |
| EBITDA | $218M | $160M | XXX | XXX | XXX |
| EBITDA Margin | 29% | 22% | XXX | XXX | XXX |
| Net Profit | $127M | $142M | XXX | XXX | XXX |
| Net Margin | 17% | 20% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jiuzhou Pharmaceutical's stock price is CNY 13 (or $2).
Jiuzhou Pharmaceutical has current market cap of CNY 11.4B (or $1.6B), and EV of CNY 9.1B (or $1.3B).
See Jiuzhou Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.6B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jiuzhou Pharmaceutical has market cap of $1.6B and EV of $1.3B.
Jiuzhou Pharmaceutical's trades at 1.7x LTM EV/Revenue multiple, and 7.3x LTM EBITDA.
Analysts estimate Jiuzhou Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jiuzhou Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 7.8x | XXX | XXX | XXX |
| P/E | 18.8x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 88.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJiuzhou Pharmaceutical's NTM/LTM revenue growth is 11%
Jiuzhou Pharmaceutical's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $24K for the same period.
Over next 12 months, Jiuzhou Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jiuzhou Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jiuzhou Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 33% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $24K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 16% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiuzhou Pharmaceutical acquired XXX companies to date.
Last acquisition by Jiuzhou Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiuzhou Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jiuzhou Pharmaceutical founded? | Jiuzhou Pharmaceutical was founded in 1973. |
| Where is Jiuzhou Pharmaceutical headquartered? | Jiuzhou Pharmaceutical is headquartered in China. |
| How many employees does Jiuzhou Pharmaceutical have? | As of today, Jiuzhou Pharmaceutical has 4.9K+ employees. |
| Is Jiuzhou Pharmaceutical publicy listed? | Yes, Jiuzhou Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical trades under 603456 ticker. |
| When did Jiuzhou Pharmaceutical go public? | Jiuzhou Pharmaceutical went public in 2014. |
| Who are competitors of Jiuzhou Pharmaceutical? | Similar companies to Jiuzhou Pharmaceutical include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's current market cap is $1.6B |
| What is the current revenue of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's last 12-month revenue is $736M. |
| What is the current EBITDA of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's last 12-month EBITDA is $172M. |
| What is the current EV/Revenue multiple of Jiuzhou Pharmaceutical? | Current revenue multiple of Jiuzhou Pharmaceutical is 1.7x. |
| What is the current EV/EBITDA multiple of Jiuzhou Pharmaceutical? | Current EBITDA multiple of Jiuzhou Pharmaceutical is 7.3x. |
| What is the current revenue growth of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical revenue growth between 2023 and 2024 was -7%. |
| Is Jiuzhou Pharmaceutical profitable? | Yes, Jiuzhou Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
